Tiziana life sciences announces purchase of common shares by chief medical officer

New york, sept. 09, 2022 (globe newswire) -- tiziana life sciences ltd.(nasdaq: tlsa) (“tiziana” or the “company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that matthew davis, its chief medical officer, purchased 100,000 common shares at $0.76 per share.

TLSA Ratings Summary

TLSA Quant Ranking